Screener
MaxLinear MXL R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by MaxLinear in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: MaxLinear’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001288469-26-000051
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of net revenue | 71,184 | 47,288 | 129,488 | 89,390 |
| Gross profit | 97,663 | 61,525 | 176,547 | 115,356 |
| Operating expenses: | ||||
| Research and development | 56,033 | 47,199 | 109,195 | 102,656 |
| Selling, general and administrative | 45,751 | 33,361 | 88,208 | 69,950 |
| Restructuring charges | 64 | 5,580 | 538 | 13,459 |
| Total operating expenses | 101,848 | 86,140 | 197,941 | 186,065 |
| Loss from operations | (4,185) | (24,615) | (21,394) | (70,709) |
Item 1. Financial Statements (unaudited)
FAQ
- What is MaxLinear's R&D?
- MaxLinear (MXL) reported R&D of $56.03M in Q2 2026.
- How has MaxLinear's R&D changed year-over-year?
- MaxLinear's R&D increased by 18.7% year-over-year, from $47.2M to $56.03M.
- What is the long-term trend for MaxLinear's R&D?
- Over 4 years (2021 to 2025), MaxLinear's R&D has grown at a -7.0% compound annual growth rate (CAGR), from $278.44M to $208.6M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about MaxLinear's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude